-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AQrEt1vEyquFO5gBsvNPjrPFVamuk1+3FNOPDZSJ/rmXvoMnXZOKVlqMc4wlDTNB g+TWjkvkX1nvG7fWKLhxaA== 0000950123-03-000781.txt : 20030131 0000950123-03-000781.hdr.sgml : 20030131 20030131093031 ACCESSION NUMBER: 0000950123-03-000781 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030128 ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20030131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERCK & CO INC CENTRAL INDEX KEY: 0000064978 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221109110 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-03305 FILM NUMBER: 03533254 BUSINESS ADDRESS: STREET 1: ONE MERCK DR STREET 2: P O BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 BUSINESS PHONE: 9084234044 MAIL ADDRESS: STREET 1: ONE MERCK DR STREET 2: PO BOX 100 WS3AB-05 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 8-K/A 1 y83035a1e8vkza.txt AMENDMENT #1 TO 1/28/03 8-K: MERCK & CO., INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 28, 2003 ------------------------------- MERCK & CO., Inc. ------------------------------------------------------------------------------- (Exact Name of Registrant as Specified in Its Charter) New Jersey ------------------------------------------------------------------------------- (State or Other Jurisdiction of Incorporation) 1-3305 22-1109110 - ----------------------------------- -------------------------------------- (Commission File Number) (I.R.S. Employer Identification No.) One Merck Drive, PO Box 100, Whitehouse Station, NJ 08889-0100 - -------------------------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code (908) 423-1000 ------------------------------ Amendment No. 1 The Registrant hereby amends its Current Report on Form 8-K, dated January 28, 2003, and furnished to the Securities and Exchange Commission on January 28, 2003, for the purpose of replacing within exhibit 99(b), the following two pages: (i) 2002 Fourth Quarter Other Financial Disclosures, and (ii) Full Year 2002 over 2001 Net Product Sales Detail. This replacement is being made in order to revise (i) the total number of Medco Health subscriptions for 2002 from 549 million to 548 million and (ii) the amount of 2002 full year foreign Trusopt/Cosopt sales from $170 million to $240 million, and the associated percentage change from (23)% to 9%. Item 7. Financial Statements and Exhibits. - ------------------------------------------ (c) Exhibits -------- Exhibit 99 Certain supplemental information Filed with related to supplemental information this document furnished on January 28, 2003 SIGNATURES ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MERCK & CO., Inc. Date: January 31, 2003 By: /s/ Debra A. Bollwage ----------------------------------- DEBRA A. BOLLWAGE Assistant Secretary EXHIBIT INDEX ------------- Exhibit Number Description - ------- ----------- 99 Certain supplemental information related to supplemental information furnished on January 28, 2003 EX-99 3 y83035a1exv99.txt CERTAIN SUPPLEMENTAL INFO TO SUPPLEMENTAL INFO Exhibit 99 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FOURTH QUARTER 2002 OTHER (INCOME)/EXPENSE, NET
4Q `02 4Q `01 YTD 2002 YTD 2001 ------ ------ -------- -------- INTEREST INCOME $ (108.1) $ (109.8) $ (419.3) $ (490.1) INTEREST EXPENSE 98.1 109.5 390.8 464.7 EXCHANGE (GAINS)/LOSSES (18.7) 15.1 (7.8) (3.5) MINORITY INTERESTS 44.5 72.3 214.2 290.6 AMORTIZATION OF GOODWILL AND INTANGIBLES 51.3 85.3 204.9 330.1 Other, net 25.1 (58.9) (79.0) (250.1) -------- -------- --------- -------- TOTAL $ 92.2 $ 113.5 $ 303.8 $ 341.7
JOINT VENTURE SALES DETAIL All sales reported here are end-market JV sales, presented on a "NET" basis, rounded to the nearest $5 million.
MERIAL 4Q `02 4Q `01 YTD 2002 YTD 2001 ------ --------- --------- ---------- -------- IVOMEC, HEARTGARD, other avermectins $ 115 $ 130 $ 465 $ 495 FRONTLINE 75 70 485 410 Biologicals 100 100 375 355 Other Animal Health 50 45 180 190 Poultry Genetics 55 55 220 210 --------- --------- ---------- -------- TOTAL MERIAL SALES $ 395 $ 400 $ 1,725 $ 1,660 Aventis Pasteur-MSD 4Q `02 4Q `01 YTD 2002 YTD 2001 ------------------- --------- --------- ---------- -------- HEPATITIS VACCINES $ 20 $ 20 $ 70 $ 90 VIRAL VACCINES 10 5 35 40 Other Vaccines 115 105 440 370 --------- --------- ---------- -------- TOTAL AP-MSD SALES $ 145 $ 130 $ 545 $ 500
Merck / Schering-Plough Collaboration 4Q `02 4Q `01 YTD 2002 YTD 2001 ------------------------------------- ------ ------ -------- -------- Zetia (Worldwide) $ 25 N/M $ 25 N/M TOTAL $ 25 N/M $ 25 N/M
TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (IN MILLIONS) 2002
MAIL RETAIL TOTAL ---- ------ ----- FIRST QUARTER 20 121 141 SECOND QUARTER 21 119 140 THIRD QUARTER 20 110 130 FOURTH QUARTER 21 117 138 ---- ------ ----- YEAR TO DATE 82 467 548
2001
MAIL RETAIL TOTAL FIRST QUARTER 18 120 138 SECOND QUARTER 19 115 134 THIRD QUARTER 18 110 128 FOURTH QUARTER 20 117 137 ---- ------ ----- YEAR TO DATE 75 462 537
Exhibit 99
MERCK & CO., INC. NET PRODUCT SALES DETAIL -------------------------------------------------------------------- FULL YEAR 2002 OVER 2001 -------------------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ----- ------ ----- ------ ------- ------- VIOXX 8% $2,530 1% $1,705 24% $ 825 ARCOXIA N/M 30 N/M -- N/M 30 VASOTEC/VASERETIC -24% 790 -100% -- -14% 790 PRINIVIL/PRINZIDE -32% 480 -33% 410 -26% 70 COZAAR/HYZAAR 21% 2,190 34% 935 13% 1,255 MEVACOR -60% 110 -76% 45 -24% 65 ZOCOR 6% 5,580 1% 3,325 14% 2,255 AGGRASTAT 0% 115 -21% 55 33% 60 SINGULAIR 19% 1,505 14% 1,090 32% 415 MAXALT 26% 295 26% 220 25% 75 PROPECIA 2% 215 -5% 100 10% 115 PROSCAR 1% 550 -2% 270 4% 280 PRIMAXIN 0% 585 12% 185 -5% 400 INVANZ N/M 15 N/M 10 N/M 5 CANCIDAS 163% 105 100% 60 N/M 45 PEPCID -80% 55 -89% 25 -50% 30 FOSAMAX 38% 2,250 34% 1,530 48% 720 CRIXIVAN/STOCRIN -25% 290 -28% 105 -23% 185 TIMOPTIC/TIMOPTIC XE -18% 165 -38% 25 -13% 140 TRUSOPT/COSOPT 5% 425 0% 185 9% 240 HEPATITIS VACCINES -12% 225 -11% 195 -14% 30 VIRAL VACCINES 11% 555 15% 530 -38% 25 OTHER VACCINES N/M 245 N/M 205 N/M 40
NOTE: Product sales rounded to the nearest $5 million. N/M - Not Meaningful -----END PRIVACY-ENHANCED MESSAGE-----